On May 24, 2024 Agendia, Inc., reported that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), taking place May 31st – June 4th, 2024, in Chicago, Illinois (Press release, Agendia, MAY 24, 2024, View Source [SID1234643701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey. These studies add to the already robust library of clinical studies demonstrating Agendia’s MammaPrint and BluePrint effectiveness in providing reliable guidance for therapeutic considerations in early-stage breast cancer.

The two abstracts that have been selected by ASCO (Free ASCO Whitepaper) for oral discussion will 1) feature an investigation of underlying biology that mediates immune therapy response and, 2) will provide an evaluation of the MammaPrint Index and 3-year recurrence-free interval in patients treated with CT, with and without anthracycline. Both presentations utilize whole transcriptome data from the prospective, observational real-word evidence FLEX Study (NCT03053193).

The following are details of the abstracts that have been accepted at the ASCO (Free ASCO Whitepaper) 2024 Annual Meeting:

Oral Discussion

Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Authors: O’Shaughnessy, J., et al.
Presenter: Joyce O’Shaughnessy, MD | Baylor-Sammons Cancer Center, Texas Oncology
Session: Rapid Oral Abstract – Breast Cancer – Local/Regional/Adjuvant
Poster Discussion: Friday, May 31, 2024 | 2:45 PM – 4:15 PM CDT
Abstract #: 511
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Authors: Cobain, E., et al.
Presenter: Erin Cobain, MD | University of Michigan Rogel Cancer Center
Session: Oral Abstract Session – Breast Cancer – Local/Regional/Adjuvant
Poster Discussion: Monday, June 3, 2024 | 3:00 PM – 6:00 PM CDT
Abstract #: 506
Poster sessions

Cost consequence model of the MammaPrint (70-gene signature) and 21-gene signature in patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Authors: Lux M.P., Sandor M. F., Hofmann V., Pronin D., Klinkhamer J.C., Müller-Huesmann H.
Presenter: Harald Müller-Huesmann | St. Josef Brothers Hospital Paderborn, Germany
Session Date & Time: Sunday, June 2, 2024 | 9:00 AM – 12:00 PM CDT
Abstract #: 534
Other Investigator Initiated Abstracts Utilizing MammaPrint + BluePrint:

Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.
Authors: Alejandro Rios-Hoyo; Lajos Pusztai
Session Date & Time: Sunday, 2, 2024 | 9:00AM-12:00PM CDT
Abstract #: 573
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint + Blueprint assay: A retrospective study.
Authors: Valdez, et al.
Abstract #: e12541
More information about the program can be found at the ASCO (Free ASCO Whitepaper) 2024 website.